SCHEMBL2954182

SCHEMBL2954182

C#CCCCNCCn1cc(C2=C(c3cccc4ccccc34)C(=O)NC2=O)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 4/20 0.65
PRKCB P05771 4/20 0.62
PRKCA P17252 4/20 0.62
PRKCH P24723 2/20 0.62
PRKCQ Q04759 2/20 0.62
PRKCD Q05655 2/20 0.62
PRKCG P05129 2/20 0.57
IDH1 O75874 1/20 0.57
PRKD3 O94806 1/20 0.57
PRKCI P41743 1/20 0.57
PRKCE Q02156 1/20 0.57
PRKCZ Q05513 1/20 0.57
PRKD1 Q15139 1/20 0.57
CCNT1 O60563 1/20 0.53
CCNA2 P20248 1/20 0.53
CDK2 P24941 1/20 0.53
CDK9 P50750 1/20 0.53
GSK3B P49841 3/20 0.50
PIM1 P11309 1/20 0.48
CDK4 P11802 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944715 0.85 CAMK2D (0.61) CAMK2DPRKCBPRKCAPRKCHPRKCQ
SCHEMBL13241407 0.83 CCNT1 (0.70) CAMK2DPRKCBPRKCAPRKCHPRKCQ
SCHEMBL4675948 0.82 CAMK2D (0.57) CAMK2DIDH1CCNT1CCNA2CDK2
SCHEMBL13241411 0.82 CCNT1 (0.76) CAMK2DPRKCACCNT1CCNA2CDK2
SCHEMBL4676702 0.82 CAMK2D (0.69) CAMK2DIDH1CCNT1CCNA2CDK2
SCHEMBL2954178 0.82 PRKCA (0.69) CAMK2DPRKCBPRKCAPRKCHPRKCQ
SCHEMBL13241410 0.81 CCNT1 (0.74) CAMK2DPRKCACCNT1CCNA2CDK2
SCHEMBL14488702 0.78 PRKCA (0.64) CAMK2DPRKCBPRKCAPRKCHPRKCQ
SCHEMBL4675538 0.76 PRKCA (1.00) CAMK2DPRKCBPRKCAPRKCHPRKCQ
SCHEMBL4681457 0.74 PRKCA (0.74) CAMK2DPRKCBPRKCAPRKCHPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS ZHANG HAN-CHENG 2010-09-23 US disclosed
US-7759380-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2010-07-20 US disclosed
US-7608634-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-10-27 US disclosed
EP-1513520-B1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed
US-20070213386-A1 Substituted pyrrolines as kinase inhibitors ZHANG HAN-CHENG 2007-09-13 US disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240650-A1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS PRKDC, MAP2K2, TTK CAMK2D 66/4885PRKCB 55/4885PRKCA 59/4885
US-20070213387-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK CAMK2D 66/4885PRKCB 55/4885PRKCA 59/4885
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK CAMK2D 66/4885PRKCB 55/4885PRKCA 59/4885
US-20070213386-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK CAMK2D 66/4885PRKCB 55/4885PRKCA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.